{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-003854","form_type":"8-K","ticker":"ALNY","cik":"0001178670","company_name":"ALNYLAM PHARMACEUTICALS, INC.","filed_at":"2024-01-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.575308+00:00","generated_at":"2026-06-07T02:00:59.912537+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Alnylam prelim 2023 product rev $1.24B (+39% YoY); Q4 growth across all drugs","bullets":["Full-year 2023 global net product revenues $1,241M, up 39% YoY (39% constant currency).","Q4 2023 revenues: ONPATTRO $79M, AMVUTTRA $175M, GIVLAARI $59M, OXLUMO $33M.","Year-end cash & investments ~$2.4B, up from $2.2B at end of 2022.","Over 4,060 patients on ONPATTRO/AMVUTTRA; over 650 on GIVLAARI, over 430 on OXLUMO at year-end 2023.","Management cites strong patient demand and commercial execution; HELIOS-B readout expected early 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-003854","json":"https://secwatch.observer/filing/0001193125-24-003854.json","markdown":"https://secwatch.observer/filing/0001193125-24-003854.md","text":"https://secwatch.observer/filing/0001193125-24-003854.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/0001193125-24-003854-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/d34101d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T02:00:59.912537+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"455d270a733a7df6c4d0de1940169d7be321c75d","claim":"ALNYLAM PHARMACEUTICALS, INC. reported fourth quarter 2023 results: revenue $346 million.","evidence_excerpt":"On January 7, 2024, Alnylam Pharmaceuticals, Inc. (the “Company”) announced its preliminary fourth quarter and full year 2023 global net product revenues of approximately $346 million and $1,241 million, respectively, for ONPATTRO® (patisiran), AMVUTTRA® (vutrisiran), GIVLAARI® (givosiran) and OXLUMO® (lumasiran).","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/0001193125-24-003854-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter 2023"},{"label":"Revenue","value":"$346 million"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"},{"claim_id":"df997cc3c2325877c707cffdfac03d1563b8b9d9","claim":"ALNYLAM PHARMACEUTICALS, INC. reported full year 2023 results: revenue $1,241 million.","evidence_excerpt":"On January 7, 2024, Alnylam Pharmaceuticals, Inc. (the “Company”) announced its preliminary fourth quarter and full year 2023 global net product revenues of approximately $346 million and $1,241 million, respectively, for ONPATTRO® (patisiran), AMVUTTRA® (vutrisiran), GIVLAARI® (givosiran) and OXLUMO® (lumasiran).","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1178670/000119312524003854/0001193125-24-003854-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"full year 2023"},{"label":"Revenue","value":"$1,241 million"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}